Related references
Note: Only part of the references are listed.Episodic and chronic migraine in children
Paul E. Youssef et al.
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2020)
Gepants for the treatment of migraine
Andrea Negro et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Therapeutic novelties in migraine: new drugs, new hope?
Thien Phu Do et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults
Peter J. Goadsby et al.
CEPHALALGIA (2019)
Recent Advances in Pharmacotherapy for Episodic Migraine
Calvin Chan et al.
CNS DRUGS (2019)
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine The ACHIEVE II Randomized Clinical Trial
Richard B. Lipton et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Ubrogepant for the Treatment of Migraine
David W. Dodick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015
Valery L. Feigin et al.
LANCET NEUROLOGY (2017)
PATHOPHYSIOLOGY OF MIGRAINE: A DISORDER OF SENSORY PROCESSING
Peter J. Goadsby et al.
PHYSIOLOGICAL REVIEWS (2017)
A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
Tiffini Voss et al.
CEPHALALGIA (2016)
Chronic migraine plus medication overuse headache: two entities or not?
Andrea Negro et al.
JOURNAL OF HEADACHE AND PAIN (2011)
Calcitonin gene-related peptide (CGRP) and its role in hypertension
Sarah-Jane Smillie et al.
NEUROPEPTIDES (2011)
Characterisation of CGRP receptors in human and porcine isolated coronary arteries:: Evidence for CGRP receptor heterogeneity
S Gupta et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Headache and sleep: Examination of sleep patterns and complaints in a large clinical sample of migraineurs
L Kelman et al.
HEADACHE (2005)
Consensus statement:: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine
D Dodick et al.
HEADACHE (2004)
Share Paper
